Document Detail


Hydroxyurea in the management of thalassemia intermedia.
MedLine Citation:
PMID:  20001623     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hydroxyurea (HU) is an antineoplastic agent that enhances fetal hemoglobin. The clinical significance induced by this compound is well known in sickle cell disease. This clinical significance could also be expected in beta-thalassemia patients. Although studies on beta-thalassemia major patients showed significant results, but these clinical responses are expected to be more in thalassemia intermedia (TI) patients because of lesser alpha/beta globin imbalance. Studies showed that HU therapy in TI patients has significant effects on increasing Hb levels that can cause reducing blood transfusion dependency and transfusion free in some patients, decreasing skeletal deformities and splenomegaly and increasing energy state. So HU therapy could be a useful alternative to blood transfusion in some TI patients.
Authors:
Mehran Karimi
Related Documents :
15945973 - Case report: abo discrepancy due to vancomycin complicating a transfusion reaction inve...
15916693 - An elevated venous haemoglobin concentration cannot be used as a surrogate marker for a...
12391363 - T2*-weighted mri differentiates multiple system atrophy from parkinson's disease.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hemoglobin     Volume:  33 Suppl 1     ISSN:  1532-432X     ISO Abbreviation:  Hemoglobin     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-16     Completed Date:  2010-05-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7705865     Medline TA:  Hemoglobin     Country:  England    
Other Details:
Languages:  eng     Pagination:  S177-82     Citation Subset:  IM    
Affiliation:
Pediatric Department and Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. karimim@sums.ac.ir
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents
Hemoglobins / analysis
Humans
Hydroxyurea / adverse effects,  therapeutic use*
Treatment Outcome
beta-Thalassemia / complications,  drug therapy*
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Hemoglobins; 127-07-1/Hydroxyurea

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heart disease in thalassemia intermedia.
Next Document:  Allogeneic stem cell transplantation in patients with ?-thalassemia: King Faisal Specialist Hospital...